Great Point Partners’s Silence Therapeutics SLN Stock Holding History

Great Point Partners’s Portfolio SLN Stock Details SLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.94M	Sell	450,000 -570,489	-56%	-$4.01M	0.93%	32
2026 Q1	$5.38M	Buy	1,020,489 +212,457	+26%	+$1.17M	1.24%	29
2025 Q4	$4.91M	Buy	+808,032	New	+$5.17M	1.59%	23
2022 Q4	–	Sell	-68,915	Closed	-$692K	–	53
2022 Q3	$692K	Sell	68,915 -332,534	-83%	-$3.5M	0.17%	40
2022 Q2	$4.76M	Sell	401,449 -42,994	-10%	-$522K	1.14%	28
2022 Q1	$8.44M	Hold	444,443	–	–	2.04%	20
2021 Q4	$10.6M	Buy	+444,443	New	+$10.3M	2.36%	20

Other funds holding SLN

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Great Point Partners's SLN Position: Q2 2026 in Review

Great Point Partners reduced its Silence Therapeutics (SLN) stake by 56% in Q2 2026, selling an estimated $4.01M and leaving 450,000 shares worth $4.94M. The position accounts for 0.93% of the portfolio, ranked #32.

Great Point Partners first reported a position in SLN in Q4 2021 and has held it in 7 quarters since. The position peaked at $10.6M in Q4 2021. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

Great Point Partners held 450,000 shares of Silence Therapeutics worth $4.94M as of Q2 2026.
Great Point Partners sold 570,489 Silence Therapeutics shares in Q2 2026, an estimated $4.01M.
Silence Therapeutics made up 0.93% of Great Point Partners's portfolio in Q2 2026, its #32 holding.
Great Point Partners first reported a position in Silence Therapeutics in Q4 2021 and has held it in 7 quarters since.
Great Point Partners's Silence Therapeutics position peaked at $10.6M in Q4 2021.
72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.